A research collaboration between MIT and Stanford has developed a new approach intended to help the immune system recognise and attack tumours more effectively. Instead of focusing only on protein ...

Study identifies promising new treatment effective against rare liver disease A new experimental therapy may finally offer ...

Analysts are intrested in these 5 stocks: ( ($VZLA) ), ( ($COTY) ), ( ($KLRS) ), ( ($ANNX) ) and ( ($BRO) ). Here is a breakdown of their recent ...

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic stem cell ...

For decades, chronic disease management in Medicare has been hampered by a fee-for-service payment system that rewards volume and activity rather than true clinical improvement. This model created ...

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

Shares of Omeros surged after the pharmaceutical company received Food and Drug Administration approval for its Yartemlea treatment. The stock was up 78% to $15.60 on Wednesday and was briefly paused ...

Omeros (OMER) announced that the U.S. Food and Drug Administration, FDA, has approved YARTEMLE for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, TA-TMA, a ...

A conserved signaling axis linking Drosophila adipose tissue to nephrocyte function reveals how obesity can drive kidney dysfunction and points to new opportunities for therapeutic intervention.